Federal grant · project grant (b)
Novel, Bio-inspired Chloramine for Infection Eradication in Chronic Wounds - Project Summary Topical Antiseptics Are a Key Strategy in the Treatment of Infected Diabetic Foot Ulcers (DFUS) to Enhance the Opportunity to Rehabilitate and Heal. Dfus Can Result in Osteomyelitis of the Foot and Amputation of Lower Extremities. Halomine, Doing Business as Avantguard, Has Developed Avantamine, a Stabilized Chlorine Containing Chloramine, That Creates a Novel Active With Residual Efficacy to Compete in the Antiseptic Space, Providing Excellent Broad-spectrum Efficacy and No History of Resistance Generation. Chlorine Is Naturally Biocompatible Biocide Compared to Alternative Chemistries Because Our Bodies Already Utilize Chlorine: Neutrophils Take Chlorine From Salt in Bodily Fluids to Produce Hypochlorous Acid (HOCL) as an Intermediary Before Ultimately Generating Taurine Chloramine. Given the Biocompatible Nature and Naturally Skin-compatible PH Compared to Dakins Solution, Hocl Has Recently Become Popular Generally at 0.033% or Less Concentration for Wound Cleaning, But Hocl Is Limited by Stability Preventing General Use at Concentrations That Would Be Most Effective. Avantamine Is a Combination of an N-halamine Containing Monomer and Other Monomers That Improve Solubility in Water. Key Differentiators Are: Avantamine Is Broad Spectrum; the Molecules Are Too Large for Cellular Uptake, Reducing Systemic Toxicology Risk; No Resistance Generation; the Formulation Has Shown No Skin Irritability; Chlorine Is a Quick and Efficient Antimicrobial. the Proposal Is Designed to Optimize the Product Against Bacteria Found in Dfus to Decrease the Persistence of the Chronic Wounds. to This We Will: 1) Examine Efficacy Against Bacteria Using a Porcine Tissue Skin Model to Understand the Performance With a Milestone of a 3-4 Log Reduction in Cfu; and 2) Evaluate in an in Vivo Porcine Model, Which Is the Most Similar to Humans for Skin Behavior. the Goal Is to Show Improved Efficacy Over the Currently Most Effective Antiseptics.
Committed
$348,150
Paid out
$250.0K
72%
Committed, not yet paid
$98.2K
28%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.